Why the study?
Coronary heart disease is a leading cause of death in women, and findings regarding the role of estrogen and timing of hormone replacement therapy in prevention have evolved.
What is the role of HRT, non-estrogen therapies, and lifestyle modifications in the primary prevention of coronary heart disease in women?
What is the role of HRT, non-estrogen therapies, and lifestyle modifications in the primary prevention of coronary heart disease in women?
This consensus statement highlights that estrogen therapy may protect against CHD in women if initiated before age 60, alongside other preventive strategies.
Answers are grounded in this paper and cite their sources.
Supports early post-menopause HRT initiation for CHD prevention; confirms timing hypothesis from WHI reanalyses and RCT meta-analyses.
Coronary heart disease (CHD) is a leading cause of death in women. Observational studies have consistently shown estrogen to help prevent CHD in postmenopausal women. The large randomised controlled Women's Health Initiative (WHI) trial initially did not confirm these observational findings. However, further analyses of the WHI study as well as meta-analyses of randomised clinical trials of hormone replacement therapy (HRT) and of the observational Nurses' Health Study have now found that the timing of onset of HRT use is important and that estrogen may have an important protective role in CHD, particularly in women initiating treatment below age 60 years. This BMS consensus statement will examine the evidence regarding HRT and non-estrogen therapies (lipid lowering agents, aspirin, antihypertensives, antidiabetic medications, SERMs) as well as diet, lifestyle and smoking cessation in the primary prevention of CHD in women.
No takes yet. Share an insight, caveat, or question.
John Stevenson (2026) conducted a review in Coronary heart disease. Hormone replacement therapy and non-estrogen therapies was evaluated. Estrogen may have an important protective role in coronary heart disease, particularly in women initiating hormone replacement therapy below age 60 years.
Synapse has enriched 10 related papers. Consider them for comparative context: